Moderna Therapeutics, Inc.

Alnylam Pharmaceuticals, Inc.

Modernatx, Inc.

Biogen Idec Ma Inc.

US Government as Represented by the Secretary of the Army

Novartis Ag

Arrowhead Pharmaceuticals, Inc.

Biogen Ma Inc.

Other

Imperial College of Science, Technology and Medicine

Arrowhead Research Corporation

Imperial Innovations Limited

Curagen Corporation

Arbutus Biopharma Corporation

Endres, Stefan, Prof. Dr.

Antonin De Fougerolles

Tirtha Chakraborty

Tatiana Novobrantseva

Sayda Mahgoub Elbashir

Kristy M Wood

Gregory Hinkle

Jason P Schrum

Stephane Bancel

Atanu Roy

Susan Whoriskey

Jeff Lynn Ellsworth

Victor E Kotelianski

Justin Guild

Kenechi Ejebe

Stuart Milstein

John Louis Diener

Emma Hickman

Pamela Tan

Anna Borodovsky

Ellen A Garber

Sina Bavari

Ron Weiss

Akin Akinc

Philipp Hadwiger

Muthiah Manoharan

Kallanthottathil G Rajeev

Brian R Bettencourt

Paul Hatala

Matthias John

Anne-Marie Pulichino

Andrew Griffin Sprague

Kelly Lyn Warfield

Carl Reid

Stephen G Hoge

Maria Frank-Kamenetsky

Roy R Lobb

Philip Gotwals

Noubar Boghos Afeyan

Jose William Saldanha

Catherine A Hession

Jens Harborth

Herman Van Vlijmen

Divakar Ramakrishnan

John P Carulli

Maria Gabriela Belvisi

Elizabeth Louise Hardaker

Suhaib Siddiqi

Staci Sabnis

Andrew W Fraley

Cynthia A Green

Pedro M Valencia

Andrew Sprague

Mark Andrew Birrell

Matthew Copeland Catley

Rachel E Meyers

Hans-Peter Vornlocher

Birgit Bramlage

Gunther Hartmann

Örn Almarsson

Gregory Sieczkiewicz

Veit Hornung

Stefan Endres

John Podobinski

Kallanthottahil G Rajeev

Yuxun Wang

Christopher R Conlee

David D Hile

Ciarán Lawlor

Anke Geicke

Mark Tracy

John Carulli

Victor E Koteliansky

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.

Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA

Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

Delivery and formulation of engineered nucleic acids

The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

Organic compositions to treat beta-ENaC-related diseases

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

In vivo production of proteins

Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions

Organic compositions to treat Beta-ENaC-related diseases

A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.

Method for the treatment of inflammatory disorders

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Modified polynucleotides for the production of proteins

Modified polynucleotides for the production of secreted proteins

Modified polynucleotides for the production of biologics and proteins associated with human disease

Modified polynucleotides for the production of proteins associated with human disease

The present disclosure relates to RNAi agents useful in methods of treating BetaENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

Growing community of inventors

Brookline, MA, United States of America

Antonin De Fougerolles